
<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>Efficacy and safety profile of oral creatine monohydrate in add-on to cognitive-behavioural therapy in depression: An 8-week pilot, double-blind, randomised, placebo-controlled feasibility and exploratory trial in an under-resourced area</title>
    <style>
        body {
            font-family: Arial, sans-serif;
            line-height: 1.6;
            color: #333;
            max-width: 800px;
            margin: 0 auto;
            padding: 20px;
        }
        h1, h2, h3, h4, h5, h6 {
            color: #2c3e50;
        }
        .toc {
            background-color: #f8f9fa;
            padding: 20px;
            border-radius: 5px;
            margin-bottom: 20px;
        }
        .toc ul {
            list-style-type: none;
            padding-left: 20px;
        }
        .section {
            margin-bottom: 30px;
            border-bottom: 1px solid #eee;
            padding-bottom: 20px;
        }
        .quote {
            background-color: #e7f4ff;
            border-left: 5px solid #3498db;
            padding: 10px;
            margin: 10px 0;
            font-style: italic;
        }
        .key-point {
            margin: 10px 0;
            padding: 10px;
            border-radius: 4px;
        }
        .key-point.strength {
            background-color: #e8f5e9;
            border-left: 4px solid #4caf50;
        }
        .key-point.suggestion {
            background-color: #fff3e0;
            border-left: 4px solid #ff9800;
        }
        .back-to-top {
            position: fixed;
            bottom: 20px;
            right: 20px;
            background-color: #3498db;
            color: white;
            padding: 10px 15px;
            border-radius: 5px;
            text-decoration: none;
            display: none;
        }
        details {
            background-color: #f9f9f9;
            border: 1px solid #ddd;
            border-radius: 4px;
            margin-bottom: 10px;
        }
        summary {
            padding: 10px;
            cursor: pointer;
            font-weight: bold;
            background-color: #f0f0f0;
        }
        details > * {
            padding: 10px;
        }
        .critique-section {
            margin-bottom: 15px;
            padding: 10px;
            background-color: #f9f9f9;
            border-radius: 4px;
        }
        .critique-title {
            font-weight: bold;
            margin-bottom: 10px;
            color: #2c3e50;
        }
    </style>
</head>
<body>
    <h1>Efficacy and safety profile of oral creatine monohydrate in add-on to cognitive-behavioural therapy in depression: An 8-week pilot, double-blind, randomised, placebo-controlled feasibility and exploratory trial in an under-resourced area</h1>
    
    <div class="toc">
        <h2>Table of Contents</h2>
        <ul>
            <li><a href="#overall-summary">Overall Summary</a></li>
            <li><a href="#section-analysis">Section Analysis</a>
                <ul>
                <li><a href="#section-0">Abstract</a></li><li><a href="#section-1">Introduction</a></li><li><a href="#section-2">Methods</a></li><li><a href="#section-3">Results</a></li><li><a href="#section-4">Discussion</a></li>
                </ul>
            </li>
        </ul>
    </div>
    
    <div id="overall-summary" class="section">
        <h2>Overall Summary</h2>
        
        <h3>Overview</h3>
        <p>In this randomized, double-blind, placebo-controlled pilot study (N=100), participants with depression received either creatine (5g/day) or placebo alongside biweekly CBT for 8 weeks. The creatine + CBT group showed a statistically significant reduction in PHQ-9 scores (mean difference = -5.12) compared to the placebo + CBT group. Both groups had similar dropout rates (40%) and adverse event profiles, with creatine associated with more gastrointestinal issues and muscle cramps.  ITT and PP analyses confirmed the primary outcome. Secondary outcomes (treatment acceptability, tolerability, safety) showed no significant differences between groups.</p>
        
        <h3>Key Points</h3>
        
    <div class="key-point strength">
        <strong>Clear Presentation of Main Findings</strong> (written-content)
        <br>
        The abstract clearly presents the main finding of reduced PHQ-9 scores in the creatine + CBT group.
        <br>
        <em>Section: Abstract</em>
    </div>
    
    <div class="key-point suggestion">
        <strong>Expand on Methodology</strong> (written-content)
        <br>
        The abstract lacks crucial methodological details like study design, sample size, and specific interventions, limiting its informativeness.
        <br>
        <em>Section: Abstract</em>
    </div>
    
    <div class="key-point strength">
        <strong>Clear Rationale and Context</strong> (written-content)
        <br>
        The introduction effectively establishes the context and rationale by highlighting the prevalence of depression and limitations of current treatments.
        <br>
        <em>Section: Introduction</em>
    </div>
    
    <div class="key-point suggestion">
        <strong>Clarify Research Gap and Question</strong> (written-content)
        <br>
        The introduction could be strengthened by explicitly stating the research gap and primary research question.
        <br>
        <em>Section: Introduction</em>
    </div>
    
    <div class="key-point strength">
        <strong>Comprehensive Description of Study Design</strong> (written-content)
        <br>
        The methods section provides a comprehensive description of the study design, including randomization, blinding, and placebo control, enhancing rigor.
        <br>
        <em>Section: Methods</em>
    </div>
    
    <div class="key-point suggestion">
        <strong>Provide More Details about the CBT Intervention</strong> (written-content)
        <br>
        The methods section lacks detailed information about the CBT intervention, limiting reproducibility.
        <br>
        <em>Section: Methods</em>
    </div>
    
    <div class="key-point strength">
        <strong>Clear Presentation of Primary Outcome and Participant Flow</strong> (written-content)
        <br>
        The results section clearly presents the primary outcome and participant flow, enhancing transparency.
        <br>
        <em>Section: Results</em>
    </div>
    
    <div class="key-point suggestion">
        <strong>Enhance Visuals and Adverse Event Reporting</strong> (written-content)
        <br>
        The results section would benefit from a visual representation of the primary outcome data and more detailed adverse event information.
        <br>
        <em>Section: Results</em>
    </div>
    
    <div class="key-point strength">
        <strong>Clear and Accurate Participant Flow Chart</strong> (graphical-figure)
        <br>
        Figure 1 clearly presents participant flow, adhering to CONSORT guidelines and accurately representing the study design.
        <br>
        <em>Section: Results</em>
    </div>
    
    <div class="key-point strength">
        <strong>Comprehensive Baseline Characteristics Table</strong> (graphical-figure)
        <br>
        Table 1 effectively summarizes baseline characteristics, demonstrating comparability between groups.
        <br>
        <em>Section: Results</em>
    </div>
    
    <div class="key-point suggestion">
        <strong>Improve Clarity and Readability of Outcome Table</strong> (graphical-figure)
        <br>
        Table 2 presents key outcome data but could be improved by clarifying the presentation of PHQ-9 scores and separating raw numbers from percentages for secondary outcomes.
        <br>
        <em>Section: Results</em>
    </div>
    
    <div class="key-point strength">
        <strong>Effective Contextualization and Transparency</strong> (written-content)
        <br>
        The discussion effectively connects the findings to existing literature and acknowledges study limitations.
        <br>
        <em>Section: Discussion</em>
    </div>
    
    <div class="key-point suggestion">
        <strong>Explore Mechanisms and Clinical Implications</strong> (written-content)
        <br>
        The discussion could be enhanced by elaborating on potential mechanisms of creatine-CBT synergy and discussing clinical implications.
        <br>
        <em>Section: Discussion</em>
    </div>
    
        
        <h3>Conclusion</h3>
        <p>This pilot study presents promising, albeit preliminary, evidence supporting the potential of creatine supplementation as an adjunct to CBT for depression. The randomized, double-blind, placebo-controlled design, and the use of ITT analysis are methodological strengths.  The significant reduction in PHQ-9 scores in the creatine + CBT group compared to the placebo + CBT group is a noteworthy finding. However, the high dropout rate, lack of detailed information on the CBT protocol, limited visual representation of results, and the absence of p-values for secondary outcomes raise concerns.  While the study&#x27;s findings align with previous research on creatine&#x27;s antidepressant effects, the limited sample size and potential confounding factors necessitate cautious interpretation.  Larger, more rigorous trials with longer follow-up periods are needed to confirm these findings, explore the mechanisms of creatine-CBT synergy, and determine the clinical implications for diverse patient populations.</p>
    </div>
    
    <div id="section-analysis" class="section">
        <h2>Section Analysis</h2>
        
        <div id="section-0" class="section">
            <h3>Abstract</h3>
            
            <h4>Key Aspects</h4>
            <ul>
            <li><strong>Study Rationale and Objective:</strong> This study investigated the efficacy and safety of creatine monohydrate as a supplement to cognitive-behavioral therapy (CBT) for depression.  Imagine creatine as a helper molecule that supports the energy factories (mitochondria) in your brain cells.  Sometimes, these factories don&#x27;t run smoothly in people with depression. Creatine may help boost their function, potentially improving mood and response to therapy.  The researchers wanted to see if adding creatine to CBT would lead to a greater improvement in depression symptoms compared to CBT alone.</li><li><strong>Study Design and Participants:</strong> The study was a randomized, double-blind, placebo-controlled trial.  This is like flipping a coin to decide which treatment group each participant joins. &quot;Double-blind&quot; means neither the participants nor the researchers knew who was getting creatine and who was getting the placebo (starch). This helps prevent bias and ensures the results are due to the treatment itself, not expectations. One hundred participants with depression were randomly assigned to either creatine + CBT or placebo + CBT for 8 weeks.</li><li><strong>Outcome Measures:</strong> The primary outcome was the change in depression severity, measured using the Patient Health Questionnaire-9 (PHQ-9). Think of the PHQ-9 as a ruler for measuring depression symptoms.  A higher score means more severe depression.  The researchers also looked at treatment acceptability (dropouts for any reason), tolerability (dropouts due to side effects), and safety (occurrence of side effects).</li><li><strong>Key Findings:</strong> After 8 weeks, both groups showed improvement, but the creatine + CBT group had significantly lower PHQ-9 scores, meaning their depression symptoms decreased more.  The difference between the groups was clinically meaningful, suggesting creatine provided a substantial benefit.  Dropout rates and side effects were similar in both groups, indicating creatine was safe and tolerable.</li><li><strong>Conclusions and Implications:</strong> This pilot study suggests that creatine could be a helpful and safe addition to CBT for depression.  It&#x27;s like adding an extra tool to the toolbox for treating depression.  However, the researchers acknowledge the need for larger, longer-term studies to confirm these findings and explore the long-term effects of creatine supplementation.</li>
            </ul>
            
            <h4>Strengths</h4>
            <ul>
            
    <li>
        <strong>Clear presentation of main findings</strong>
        <p>The abstract clearly presents the main findings of the study, highlighting the significant reduction in PHQ-9 scores in the creatine + CBT group compared to the placebo + CBT group. This key result is effectively communicated, allowing readers to quickly grasp the study&#x27;s primary outcome.</p>
        <div class="quote">"At 8 weeks, PHQ-9 scores were lower in both study arms, but significantly more so in participants taking creatine (mean difference= -5.12)." (Page 1)</div>
    </li>
    
            </ul>
            
            <h4>Suggestions for Improvement</h4>
            <ul>
            
    <li>
        <strong>Expand on methodology</strong>
        
        <p>This is a high-impact improvement that would enhance the clarity and completeness of the abstract.  The abstract should provide a concise summary of the study&#x27;s methodology, including the type of study design, the sample size, and the intervention and comparator details. This information is crucial for readers to understand the study&#x27;s context and assess the validity of the findings. Providing these details upfront allows readers to quickly evaluate the study&#x27;s relevance and rigor. Including this information in the abstract would significantly improve its informativeness and allow readers to quickly assess the study&#x27;s design and scope.</p>
        <div class="quote">"In this pilot feasibility and exploratory study, we investigate the 8-week effects of creatine in addition to cognitive-behavioural therapy (CBT) versus placebo plus CBT in depression." (Page 1)</div>
        <p><strong>Implementation:</strong> Include details about the study design (pilot, randomized, placebo-controlled, double-blind), the total sample size (N=100), and the specific interventions used (5g/day creatine monohydrate + biweekly CBT vs. 5g/day starch placebo + biweekly CBT).  For example: &quot;In this pilot, randomized, double-blind, placebo-controlled trial (N=100), we investigated the 8-week effects of 5g/day creatine monohydrate plus biweekly CBT compared to 5g/day starch placebo plus biweekly CBT in adults with depression.&quot;</p>
    </li>
    
            </ul>
            
            
        </div>
        
        <div id="section-1" class="section">
            <h3>Introduction</h3>
            
            <h4>Key Aspects</h4>
            <ul>
            <li><strong>Prevalence and Burden of Depression:</strong> Major depressive disorder affects a large number of people worldwide, posing a significant health burden.  It&#x27;s like a widespread energy crisis in the brain, affecting mood, motivation, and even basic bodily functions.  Current treatments, while effective for many, leave a substantial portion of patients struggling to find relief. This unmet need drives the search for new strategies to improve depression care.</li><li><strong>Creatine as a Potential Antidepressant:</strong> Creatine, a naturally occurring compound involved in energy metabolism, has shown promise in preclinical and clinical studies as a potential treatment for depression.  Think of creatine as a kind of battery backup for brain cells, helping them maintain stable energy levels.  Research suggests that low creatine levels in the brain may contribute to depression and hinder treatment response.  Creatine&#x27;s neuroprotective properties and interactions with neurotransmitter systems further support its potential as an antidepressant.</li><li><strong>CBT and its Limitations:</strong> Cognitive Behavioral Therapy (CBT) is a widely used and effective treatment for depression.  It&#x27;s like retraining the brain&#x27;s software, helping people identify and change negative thought patterns and behaviors that contribute to depression.  While CBT is generally effective, some individuals experience slow or limited response.  Researchers are exploring ways to boost CBT&#x27;s effectiveness, and creatine&#x27;s potential to improve cognitive function makes it a promising candidate.</li><li><strong>Rationale for Combining Creatine and CBT:</strong> This study investigates the combined effects of creatine supplementation and CBT for depression.  It&#x27;s like combining hardware and software upgrades for the brain, potentially leading to synergistic improvements.  The study aims to determine whether adding creatine to CBT can enhance symptom reduction compared to CBT alone, offering a new approach to improve treatment outcomes.</li>
            </ul>
            
            <h4>Strengths</h4>
            <ul>
            
    <li>
        <strong>Clear rationale and context</strong>
        <p>The introduction effectively establishes the prevalence and burden of major depressive disorder, providing a clear rationale for the study by highlighting the limitations of current treatments.</p>
        <div class="quote">"Major depressive disorder has a large prevalence (&gt; 350 million people worldwide) and burden of disease (GBD 2019 Mental Disorders Collaborators, 2022)." (Page 1)</div>
    </li>
    
            </ul>
            
            <h4>Suggestions for Improvement</h4>
            <ul>
            
    <li>
        <strong>Explicitly state the research gap</strong>
        
        <p>This is a high-impact improvement that would enhance the introduction&#x27;s clarity and completeness. The introduction should explicitly state the research gap being addressed. While the introduction mentions the limitations of current treatments, it doesn&#x27;t explicitly state that the combination of creatine with CBT hasn&#x27;t been studied before.  Clearly stating this gap would strengthen the rationale for the study and highlight its novel contribution.  This would also help readers understand the specific knowledge gap the study aims to fill.</p>
        <div class="quote">"In this context, creatine could enhance the effects of CBT by promoting cognitive and behavioural functioning while also expressing a direct antidepressant action – but to present this has not been tested in a clinical trial setting." (Page 2)</div>
        <p><strong>Implementation:</strong> Add a sentence explicitly stating the research gap. For example: &quot;However, the potential of creatine supplementation as an adjunct to CBT for depression remains unexplored.&quot;</p>
    </li>
    
    <li>
        <strong>Clearly state the research question</strong>
        
        <p>This is a medium-impact improvement that would enhance the introduction&#x27;s clarity and flow. The introduction should clearly state the primary research question or hypothesis. While the introduction implies the research question, explicitly stating it would improve the reader&#x27;s understanding of the study&#x27;s objective. This would also help focus the introduction and ensure all background information directly relates to the primary research question.</p>
        <div class="quote">"Thus, in this proof-of-concept study, we investigate the 8-week augmentative antidepressant efficacy, acceptability, tolerability, and safety of creatine by combining oral creatine monohydrate with CBT against placebo with CBT in a community sample of patients diagnosed with depression." (Page 2)</div>
        <p><strong>Implementation:</strong> Add a sentence clearly stating the primary research question. For example: &quot;This study aims to investigate whether creatine monohydrate supplementation enhances the effectiveness of CBT in reducing depressive symptoms compared to CBT alone.&quot;</p>
    </li>
    
            </ul>
            
            
        </div>
        
        <div id="section-2" class="section">
            <h3>Methods</h3>
            
            <h4>Key Aspects</h4>
            <ul>
            <li><strong>Study Design:</strong> This 8-week study was designed as a randomized, double-blind, placebo-controlled trial.  Randomization, like flipping a coin, ensures that participants are assigned to either the creatine or placebo group by chance, minimizing bias.  Blinding, like wearing a blindfold, means that neither the participants nor the researchers knew who was receiving creatine or the placebo (starch). This prevents expectations from influencing the results.  The placebo-controlled design allows for a direct comparison between the effects of creatine and a neutral substance, isolating the specific impact of creatine.</li><li><strong>Participants:</strong> One hundred participants diagnosed with depression participated in the study.  They were recruited from three sites in Dehradun, India, and screened using a semi-structured interview and the SCID-5 to confirm their diagnosis.  Inclusion criteria included age 18-60, a PHQ-9 score ≥ 5, and no other significant physical or mental disorders.  Exclusion criteria included bipolar disorder, psychotic depression, substance misuse, and current use of psychotropic medications.  This careful selection process aimed to ensure a homogenous sample and minimize confounding factors.</li><li><strong>Interventions:</strong> Participants were randomly assigned to receive either 5g/day of creatine monohydrate or 5g/day of starch placebo, both administered orally in capsules identical in appearance, odor, taste, and packaging.  In addition to the supplement/placebo, all participants received biweekly individual CBT sessions.  Creatine, a naturally occurring compound, plays a role in energy metabolism, while starch serves as an inert placebo.  CBT, a type of psychotherapy, helps individuals identify and change negative thought patterns and behaviors.  The combined intervention aimed to explore the potential synergistic effects of creatine and CBT.</li><li><strong>Outcome Measures:</strong> The primary outcome was the change in depression severity from baseline to week 8, measured using the PHQ-9.  The PHQ-9 is a questionnaire that assesses the severity of depression symptoms, with higher scores indicating more severe depression.  Secondary outcomes included treatment acceptability (dropout rates for any reason), tolerability (dropout rates due to adverse events), and safety (proportion of participants experiencing adverse events).  These outcomes were assessed using a pre-specified Side Effect Questionnaire (SEQ).  These measures allowed the researchers to evaluate the effectiveness, feasibility, and safety of the combined creatine-CBT intervention.</li><li><strong>Statistical Analysis:</strong> The study employed an intention-to-treat (ITT) analysis, which includes all randomized participants regardless of whether they completed the study.  This approach minimizes bias and provides a realistic estimate of the intervention&#x27;s effectiveness in a real-world setting.  Missing data were handled using multiple imputation, a statistical technique that fills in missing values based on the observed data.  For the primary outcome, an analysis of covariance (ANCOVA) was used, adjusting for age, sex, and baseline depression scores.  Secondary outcomes were analyzed using logistic regression.  These statistical methods allowed for a rigorous comparison between the creatine + CBT and placebo + CBT groups.</li>
            </ul>
            
            <h4>Strengths</h4>
            <ul>
            
    <li>
        <strong>Clear description of study design</strong>
        <p>The methods section clearly outlines the study design as a pilot, randomized, parallel-arm, placebo-controlled, double-blind, feasibility, and exploratory trial. This comprehensive description allows readers to understand the study&#x27;s structure and the measures taken to minimize bias and ensure rigor.</p>
        <div class="quote">"This study is a pilot (phase 2, nutraceuticals), randomised, parallel-arm, placebo-controlled, double-blind, feasibility and exploratory trial" (Page 2)</div>
    </li>
    
            </ul>
            
            <h4>Suggestions for Improvement</h4>
            <ul>
            
    <li>
        <strong>Provide more details about the CBT intervention</strong>
        
        <p>This is a high-impact improvement that would enhance the reproducibility of the study.  The Methods section should provide detailed information about the CBT intervention, including the specific techniques used, the duration of each session, and the qualifications of the therapist. This information is crucial for other researchers to replicate the intervention and assess the generalizability of the findings.  Providing these details would strengthen the study&#x27;s methodological rigor and contribute to the cumulative knowledge in the field.  Ultimately, a more detailed description of the CBT intervention would significantly improve the study&#x27;s scientific contribution and facilitate future research.</p>
        <div class="quote">"The common comparator (i.e., individual CBT) was delivered with low frequency (biweekly)" (Page 2)</div>
        <p><strong>Implementation:</strong> Include details about the specific CBT techniques used (e.g., cognitive restructuring, behavioral activation), the duration and number of sessions, and the qualifications and experience of the therapist delivering the CBT intervention. For example: &quot;The CBT intervention consisted of five 45-minute sessions delivered biweekly by a board-registered clinical psychologist (SD) with 5 years of experience in CBT. The sessions included techniques such as...&quot;.</p>
    </li>
    
            </ul>
            
            
        </div>
        
        <div id="section-3" class="section">
            <h3>Results</h3>
            
            <h4>Key Aspects</h4>
            <ul>
            <li><strong>Baseline Characteristics:</strong> One hundred participants with depression, evenly split between male and female, enrolled in the study. Their average age was around 30, and their average BMI suggested they were slightly overweight.  Their initial PHQ-9 scores indicated moderately severe depression, ranging from mild to severe cases.  These baseline characteristics are important because they describe the study population and help us understand who the findings might apply to.  It&#x27;s like taking a snapshot of the participants&#x27; health before the study begins, so we can see how much they change over time.</li><li><strong>Primary Outcome: Depression Severity:</strong> The main finding of the study was that the group receiving creatine along with CBT had significantly lower depression scores after 8 weeks compared to the group receiving placebo and CBT.  The average PHQ-9 score in the creatine group dropped to 5.8, indicating mild depression, while the placebo group&#x27;s average score remained at 11.9, indicating moderate depression.  This difference suggests that creatine might boost the effectiveness of CBT.  It&#x27;s like adding fertilizer to a plant to help it grow stronger – the CBT provides the basic framework, and the creatine may enhance its effects.</li><li><strong>Treatment Discontinuation:</strong> A large number of participants, 40% in each group, dropped out of the study before the 8-week mark.  Some left due to side effects, while others were lost to follow-up or discontinued the intervention.  The dropout rates were similar between the creatine and placebo groups, suggesting that creatine didn&#x27;t cause more people to quit the study.  High dropout rates can make it harder to draw firm conclusions, but the researchers still analyzed the data from everyone who participated, regardless of whether they finished the study.</li><li><strong>Adverse Events:</strong> Side effects were common in both groups, with most being mild and no serious adverse events reported.  People taking creatine experienced more gastrointestinal issues like constipation and diarrhea, as well as muscle cramps.  Those in the placebo group reported more vomiting and itching.  It&#x27;s important to track side effects to understand the safety of a treatment.  While some side effects are expected, serious ones could indicate a problem.  In this case, the side effects were mostly manageable, suggesting that creatine is relatively safe to use alongside CBT.</li>
            </ul>
            
            <h4>Strengths</h4>
            <ul>
            
    <li>
        <strong>Clear presentation of primary outcome</strong>
        <p>The Results section effectively presents the primary outcome, showing a statistically significant reduction in PHQ-9 scores in the creatine + CBT group compared to the placebo + CBT group. This clear presentation of the main finding directly addresses the primary research question posed in the introduction.</p>
        <div class="quote">"PHQ-9 scores at study endpoint were lower than baseline ones for both arms: 5.8 (±4.8) for creatine + CBT arm (i.e., mild depression) and 11.9 (±6.6) for placebo + CBT arm" (Page 4)</div>
    </li>
    
    <li>
        <strong>Detailed participant flow description</strong>
        <p>The Results section provides a comprehensive account of participant flow through the study, including the number of participants screened, randomized, and completing the study. This detailed description enhances transparency and allows readers to assess the impact of attrition on the study&#x27;s findings.</p>
        <div class="quote">"A total of 156 people were assessed for eligibility: 100 participants were randomised to either the creatine + CBT arm or the placebo + CBT arm. Of these, 60 participants reached the study endpoint at 8 weeks (Fig. 1)." (Page 4)</div>
    </li>
    
            </ul>
            
            <h4>Suggestions for Improvement</h4>
            <ul>
            
    <li>
        <strong>Include visual representation of primary outcome</strong>
        
        <p>This is a high-impact improvement that would enhance the clarity and interpretability of the results. The Results section should include a clear visual representation of the primary outcome data, such as a box plot or bar graph, showing the distribution of PHQ-9 scores at baseline and endpoint for both groups. While the text describes the mean PHQ-9 scores and their statistical significance, a visual representation would make the data more accessible and easier to grasp, allowing readers to quickly compare the magnitude of change between groups.  This visual representation would significantly improve the communication of the primary outcome and enhance the overall impact of the findings.</p>
        <div class="quote">"PHQ-9 scores at study endpoint were lower than baseline ones for both arms: 5.8 (±4.8) for creatine + CBT arm (i.e., mild depression) and 11.9 (±6.6) for placebo + CBT arm" (Page 4)</div>
        <p><strong>Implementation:</strong> Include a figure (e.g., box plot or bar graph) visually displaying the distribution of PHQ-9 scores at baseline and endpoint for both the creatine + CBT and placebo + CBT groups. Clearly label the axes and include error bars representing standard deviations or confidence intervals.</p>
    </li>
    
    <li>
        <strong>Provide more detailed adverse event information</strong>
        
        <p>This is a medium-impact improvement that would enhance the completeness and transparency of the results.  The Results section should provide more detailed information about the adverse events reported in both groups, including the specific types of adverse events, their severity, and their frequency. While the text mentions some common adverse events, a more comprehensive presentation of this data, potentially in a supplementary table, would allow readers to fully assess the safety profile of creatine supplementation in this context. This detailed information would strengthen the study&#x27;s contribution to understanding the potential risks and benefits of creatine as an adjunct to CBT for depression.</p>
        <div class="quote">"Additional details on depression symptom severity scores, treatment discontinuations (due to any cause and due to adverse events), and adverse events (number of patients experiencing at least one, total number, number by type) at each timepoint are provided in Supplementary Material, S5." (Page 4)</div>
        <p><strong>Implementation:</strong> Include a supplementary table providing a detailed breakdown of all reported adverse events, including their specific type, severity (e.g., mild, moderate, severe), and frequency in each group. This table would complement the existing text and provide a more comprehensive overview of the safety data.</p>
    </li>
    
            </ul>
            
            
    <h4>Non-Text Elements</h4>
    
        <details class="non-text-element">
            <summary>Fig. 1. Study flow chart.</summary>
            
            
            
            <div class="critique-section">
                <div class="critique-title">First Reference in Text</div>
                <div class="quote">Of these, 60 participants reached the study endpoint at 8 weeks (Fig. 1).</div>
            </div>
            
            <div class="critique-section">
                <div class="critique-title">Description</div>
                
        <ul>
        <li><strong>Overall structure and purpose</strong>: The flow chart depicts the journey of participants through a randomized controlled trial (RCT). It starts with the initial pool of participants assessed for eligibility and follows them through the various stages of the study. The chart is organized chronologically, starting with the assessment for eligibility and proceeding through randomization, allocation to treatment groups, follow-up assessments, and finally, inclusion in the analysis. Each stage is represented by a box, and the connecting lines indicate the flow of participants. The number of participants at each stage is clearly indicated within or alongside each box. The chart also specifies the reasons for dropout at each time point, which may be unfamiliar to a layperson but is clearly denoted in the chart.</li><li><strong>Treatment arms and allocation</strong>: The chart uses a color-coding system to differentiate between the two treatment arms of the RCT. One arm is represented by red boxes, while the other arm is represented by green boxes, consistently throughout the chart. This clear color distinction aids in visualizing the participant flow within each treatment arm independently. The allocation of participants to these two arms is determined through a process called &#x27;randomization&#x27;, a technique used in RCTs to ensure that participants are assigned to either treatment group by chance rather than by any other factor, with the aim of minimizing bias.</li><li><strong>Dropout and study endpoint</strong>: The flow chart also illustrates the number of dropouts at each follow-up time point. &#x27;Dropout&#x27; refers to the discontinuation of a participant&#x27;s involvement in a study before its completion. The chart depicts dropouts as branches diverting from the main flow, with the number of participants who dropped out at each assessment indicated in the corresponding branch. The reasons for dropout are also specified, such as loss to follow-up (participants no longer contactable), side effects (adverse events), or discontinued intervention (participant chose to end their involvement). Dropouts are a common occurrence in clinical trials and understanding their reasons can help interpret the results of the study. In the reference text, the term &#x27;study endpoint&#x27; refers to the final assessment time point of the trial, which in this case is 8 weeks.</li></ul>
            </div>
            
            <div class="critique-section">
                <div class="critique-title">Scientific Validity</div>
                
        <ul>
        <li><strong>CONSORT guidelines adherence</strong>: The flow chart adheres to the CONSORT (Consolidated Standards of Reporting Trials) guidelines, which represent a set of evidence-based recommendations for reporting randomized controlled trials. Adherence to these guidelines enhances the transparency and completeness of reporting, which is crucial for evaluating the validity and generalizability of trial results. The clear depiction of participant flow, including randomization, allocation, follow-up, and analysis, ensures that readers can fully comprehend the study&#x27;s methodology and potential biases.</li><li><strong>Study design representation</strong>: The chart accurately represents the study design as a randomized, parallel-arm, placebo-controlled, double-blind trial. This clear presentation of the study design strengthens the study&#x27;s rigor and validity. The explicit mention of randomization and allocation procedures, as well as the use of a placebo control and blinding, highlights the study&#x27;s efforts to minimize bias and enhance the reliability of the findings. The inclusion of follow-up time points and reasons for dropout provides further insights into the conduct and results of the trial.</li><li><strong>Sample size accuracy</strong>: The flow chart correctly indicates the sample size at each stage of the study, providing a transparent and accurate representation of the study population. This detailed breakdown of participant numbers allows readers to assess the potential impact of attrition (dropout) on the study results and to gauge the representativeness of the final sample. The clear representation of sample sizes enhances the transparency and reproducibility of the study.</li></ul>
            </div>
            
            <div class="critique-section">
                <div class="critique-title">Communication</div>
                
        <ul>
        <li><strong>Clarity and organization</strong>: The flow chart clearly presents the flow of participants through the different stages of the study. The color-coding effectively distinguishes between the two treatment arms, and the use of concise labels makes the chart easy to follow. The figure effectively communicates the sample size at each stage, including the number of participants screened, randomized, allocated to each treatment arm, dropped out, and completed the study. This transparent presentation of participant flow enhances the credibility of the study by allowing readers to understand how the final sample size was reached and the reasons for attrition.</li><li><strong>Accessibility and conciseness</strong>: The figure&#x27;s caption is concise yet informative, providing context and clearly indicating the content of the chart. The labels within the chart are also clear and unambiguous, avoiding jargon and technical terms that might confuse a non-expert reader. The visual simplicity of the flow chart, combined with clear and concise labeling, makes the information readily accessible to a broad audience, including those without specialized knowledge in clinical trials.</li></ul>
            </div>
        </details>
        
        <details class="non-text-element">
            <summary>Table 1. Baseline characteristics per study arm.</summary>
            
            
            
            <div class="critique-section">
                <div class="critique-title">First Reference in Text</div>
                <div class="quote">Participants&#x27; baseline characteristics were comparable between study arms (Table 1).</div>
            </div>
            
            <div class="critique-section">
                <div class="critique-title">Description</div>
                
        <ul>
        <li><strong>Overall structure and purpose</strong>: The table presents the baseline characteristics of the participants enrolled in the randomized controlled trial (RCT), categorized by the treatment arm to which they were allocated.  &#x27;Baseline&#x27; refers to the status of the participants before any intervention is administered, allowing researchers to understand the initial characteristics of the groups being compared. The table is organized with rows representing different characteristics and two columns, one for each treatment arm: &#x27;creatine + CBT&#x27; and &#x27;placebo + CBT&#x27;.  &#x27;CBT&#x27; stands for Cognitive Behavioral Therapy, a type of psychotherapy. The table aims to demonstrate that the two groups were similar at the beginning of the study, minimizing the chance that observed differences in outcomes are due to pre-existing differences rather than the treatment itself.</li><li><strong>Specific characteristics presented</strong>: The characteristics presented in the table include demographic information like age, sex, body mass index (BMI), relationship status, years of education, and employment status. These characteristics provide a general profile of the participants in each group. It also includes the baseline PHQ-9 (Patient Health Questionnaire-9) score. The PHQ-9 is a self-reported questionnaire used to assess the severity of depressive symptoms. A higher score indicates more severe depression.</li><li><strong>Data presentation format</strong>: For categorical variables such as sex, relationship status, and employment status, the table presents both the number (N) of participants in each category and the corresponding percentage of the total number within each treatment arm. For continuous variables like age, BMI, and PHQ-9 score, the table presents the mean (average value) and standard deviation (SD), which shows how spread out the values are from the mean. Presenting both means and SDs allows for a better understanding of the distribution of these variables within each group.</li></ul>
            </div>
            
            <div class="critique-section">
                <div class="critique-title">Scientific Validity</div>
                
        <ul>
        <li><strong>Randomization effectiveness</strong>: The inclusion of baseline characteristics is a standard practice in randomized controlled trials and strengthens the internal validity of the study. Comparing baseline characteristics ensures that the randomization process has effectively distributed potential confounding factors across the treatment groups, minimizing the risk of selection bias. This helps to ensure that any observed differences in outcomes can be more confidently attributed to the intervention rather than pre-existing differences between the groups.</li><li><strong>Relevance of characteristics</strong>: The choice of baseline characteristics is appropriate and relevant to the study&#x27;s focus on depression. The inclusion of age, sex, BMI, socioeconomic indicators (education, employment), and baseline depression severity (PHQ-9) allows for a comprehensive assessment of potential confounding variables that could influence the outcome. This comprehensive assessment strengthens the validity of the study&#x27;s findings.</li><li><strong>Statistical rigor</strong>: The statistical measures used to describe the baseline characteristics are appropriate and correctly applied. Reporting means and SDs for continuous variables and frequencies and percentages for categorical variables is standard practice and provides a clear and accurate summary of the data. The use of these appropriate descriptive statistics strengthens the credibility of the presented data.</li></ul>
            </div>
            
            <div class="critique-section">
                <div class="critique-title">Communication</div>
                
        <ul>
        <li><strong>Clarity and formatting</strong>: The table is well-organized and easy to read, with clear column headings and consistent formatting. The use of descriptive labels for each characteristic and the inclusion of both raw numbers and percentages for categorical variables makes the data readily interpretable. The presentation of means and standard deviations for continuous variables is appropriate and facilitates comparison between the two study arms. The clear legend further enhances readability by explaining the abbreviations and statistical measures used.</li><li><strong>Informativeness</strong>: The table effectively summarizes the baseline characteristics of the participants in each study arm, allowing for direct comparison and assessment of baseline comparability. The presentation of demographic and clinical characteristics, including age, sex, BMI, relationship status, education, employment status, and baseline PHQ-9 score, provides a comprehensive overview of the study population. This comprehensive presentation allows readers to assess the potential influence of these baseline characteristics on the study outcomes.</li><li><strong>Conciseness</strong>: While the table presents a good amount of information, it remains concise and avoids overwhelming the reader with unnecessary details. The focus on key baseline characteristics relevant to the study&#x27;s objectives ensures that the table serves its purpose effectively without being overly complex. The use of a clear and concise legend further aids in conveying the necessary information without cluttering the table itself.</li></ul>
            </div>
        </details>
        
        <details class="non-text-element">
            <summary>Table 2. Study outcomes at 8 weeks (study endpoint).</summary>
            
            
            
            <div class="critique-section">
                <div class="critique-title">First Reference in Text</div>
                <div class="quote">Outcome data at study endpoint for both creatine + CBT and placebo + CBT arms are available in Table 2.</div>
            </div>
            
            <div class="critique-section">
                <div class="critique-title">Description</div>
                
        <ul>
        <li><strong>Overall structure and purpose</strong>: The table presents the results of the study at the 8-week endpoint, summarizing both the primary and secondary outcome measures. The primary outcome, PHQ-9 depression symptom severity, is presented as mean and standard deviation (SD) for both the creatine + CBT and placebo + CBT groups. Secondary outcomes include the proportion of participants discontinuing treatment due to any cause (acceptability), due to adverse events (tolerability), and the proportion experiencing at least one adverse event (safety). &#x27;Study endpoint&#x27; refers to the final assessment point in a clinical trial, which is 8 weeks in this study.  CBT stands for Cognitive Behavioral Therapy, a type of psychotherapy.</li><li><strong>Types of analysis</strong>: The table includes the results of both an intention-to-treat (ITT) and a per-protocol (PP) analysis. ITT analysis includes all randomized participants, regardless of whether they completed the study or adhered to the assigned treatment, preserving the benefits of randomization. PP analysis, on the other hand, only includes participants who completed the study according to the protocol. Including both analyses provides a more comprehensive understanding of the treatment effect and accounts for potential bias introduced by dropouts or non-compliance.</li><li><strong>Specific measures and statistics</strong>: For the primary outcome (PHQ-9 score), the table presents the baseline mean and SD alongside the endpoint mean and SD for both treatment arms. Additionally, the adjusted mean difference (aMD) between the two groups is presented along with its 95% confidence interval (CI). The CI provides a range of values within which the true population mean difference is likely to lie. For the secondary outcomes, the table presents the number (N) and percentage (%) of participants experiencing each outcome in both treatment arms.  Adjusted odds ratios (aOR) with their respective CIs are also reported for the secondary outcomes. The aOR represents the odds of an event occurring in one group compared to the other, after adjusting for other variables. Beta (β) coefficients are regression coefficients that help understand the impact of various predictor variables on an outcome.  The inclusion of baseline PHQ-9 score helps in assessing the change from baseline in each treatment group.</li></ul>
            </div>
            
            <div class="critique-section">
                <div class="critique-title">Scientific Validity</div>
                
        <ul>
        <li><strong>ITT and PP analyses</strong>: The inclusion of both ITT and PP analyses is commendable as it strengthens the study&#x27;s robustness and allows for assessing the impact of missing data. The ITT analysis preserves the benefits of randomization and provides a more conservative estimate of the treatment effect. The PP analysis offers insights into the treatment&#x27;s efficacy in those who adhered to the protocol. Presenting both analyses allows readers to compare the results and consider potential biases introduced by participant dropout or non-compliance.</li><li><strong>Effect size and confidence intervals</strong>: Reporting aMDs and aORs with 95% CIs for both primary and secondary outcomes is appropriate and provides crucial information about the precision and statistical significance of the observed effects. The use of appropriate statistical methods, including adjustment for potential confounders, strengthens the validity of the findings. However, the absence of p-values for secondary outcomes makes it difficult to assess the statistical significance of these results and could be improved by including them.</li><li><strong>Baseline and endpoint data</strong>: The table clearly presents the baseline and endpoint PHQ-9 scores for both treatment arms, allowing for a direct comparison of the change in depression severity. This clear presentation of both baseline and endpoint data, alongside the effect size and CI, facilitates a thorough evaluation of the treatment effect. However, the use of mixed units (mean ± SD for the PHQ-9 score and N events (%) for other variables) in the results section, while potentially reflecting different data types, could benefit from clarification to avoid potential confusion.  Ensuring consistent reporting units across outcomes would enhance clarity and comparability.</li></ul>
            </div>
            
            <div class="critique-section">
                <div class="critique-title">Communication</div>
                
        <ul>
        <li><strong>Clarity and formatting</strong>: The table is generally well-organized, but the presentation of both baseline and endpoint data for the PHQ-9 scores within the same cell can be slightly confusing. Separating these values into different rows would improve clarity. Additionally, the inclusion of both raw event numbers (N) and percentages (%) for the secondary outcomes is helpful, but the placement of both within the same cell adds to the visual clutter. Presenting these values in separate columns would enhance readability.</li><li><strong>Informativeness</strong>: The table provides essential information about the primary and secondary outcomes of the study, including effect sizes and confidence intervals, which are crucial for interpreting the results. The inclusion of both intention-to-treat (ITT) and per-protocol (PP) analyses for the primary outcome strengthens the robustness of the findings. However, the lack of p-values for the secondary outcomes makes it difficult to assess the statistical significance of these results, which limits the ability to draw definitive conclusions.</li><li><strong>Accessibility</strong>: The use of abbreviations like aMD, aOR, β, and CI, while standard in scientific literature, might not be immediately clear to all readers. Including a brief explanation of these terms in the table legend would enhance accessibility. The dense presentation of data, particularly the combination of means, SDs, and baseline values within the same cell, can make it challenging for readers to quickly grasp the key findings. Streamlining the presentation and separating these values would improve readability.</li></ul>
            </div>
        </details>
        
    
        </div>
        
        <div id="section-4" class="section">
            <h3>Discussion</h3>
            
            <h4>Key Aspects</h4>
            <ul>
            <li><strong>Creatine Augmentation Improves CBT Outcomes:</strong> The study&#x27;s primary finding is that adding creatine to CBT leads to a greater reduction in depression symptoms compared to CBT plus placebo. This is measured by the PHQ-9 score, a questionnaire where lower scores indicate less severe depression. Imagine the PHQ-9 as a dipstick measuring the level of depression in a tank. The creatine group&#x27;s dipstick shows a lower level after 8 weeks than the placebo group&#x27;s. This key finding supports the hypothesis that creatine can boost the effectiveness of CBT.</li><li><strong>Creatine-CBT is Acceptable, Tolerable, and Safe:</strong> Both the creatine and placebo groups experienced similar rates of treatment discontinuation (40%) and adverse events. This suggests that adding creatine doesn&#x27;t make CBT less tolerable or safe.  Think of it like adding a vitamin to a healthy diet 

 it might provide extra benefits, but it shouldn&#x27;t make the diet harder to stick to or cause new problems. This is important because it indicates that creatine is a feasible addition to CBT without increasing the risk of negative consequences.</li><li><strong>Confirmation of Creatine&#x27;s Antidepressant Effects:</strong> The study&#x27;s findings are consistent with previous research showing creatine&#x27;s antidepressant potential, particularly when combined with standard treatments.  It&#x27;s like adding another piece to a puzzle 

 each study adds more evidence supporting creatine&#x27;s role in improving mood.  This adds weight to the idea that creatine isn&#x27;t just a short-term fix, but a potentially valuable tool for long-term depression management.</li><li><strong>Novel Combination of Creatine and CBT:</strong> This study is the first to investigate creatine as a supplement to CBT, rather than medication. This is a novel approach because it explores creatine&#x27;s potential to enhance a non-pharmacological treatment. It&#x27;s like trying a different type of fertilizer on a plant 

 both might help it grow, but they work through different pathways. This opens up new avenues for research and could lead to more personalized treatment strategies for depression.</li><li><strong>Study Limitations and Future Directions:</strong> The study has several limitations, including a high dropout rate (40%), a relatively young and homogenous sample, and potential confounding from the COVID-19 pandemic. These limitations are like cracks in a bridge 

 they don&#x27;t necessarily mean the bridge will collapse, but they weaken its overall strength.  Acknowledging these limitations is crucial for interpreting the results cautiously and identifying areas for improvement in future research.</li>
            </ul>
            
            <h4>Strengths</h4>
            <ul>
            
    <li>
        <strong>Effective connection to existing literature</strong>
        <p>The discussion effectively connects the study&#x27;s findings to the existing literature on creatine supplementation for depression. It highlights the consistency of the current results with previous studies that used creatine as an adjunct to antidepressant medications, strengthening the argument for creatine&#x27;s potential antidepressant properties.</p>
        <div class="quote">"Nonetheless, depression scores were significantly lower when CBT was augmented with 5 mg of creatine monohydrate (both in the primary ITT analysis and in the sensitivity PP analysis), in line with the results of previous clinical trials of creatine in addition to antidepressant medications" (Page 5)</div>
    </li>
    
    <li>
        <strong>Transparent acknowledgment of limitations</strong>
        <p>The discussion acknowledges the limitations of the study, including the high dropout rate, the specific demographics of the sample, and the potential impact of the COVID-19 pandemic. This transparency strengthens the paper&#x27;s credibility and provides context for interpreting the results.</p>
        <div class="quote">"This pilot investigation of the adjunct antidepressant effects of creatine on CBT has several limitations, which emphasise the need to interpret all findings as preliminary and hypothesis-generating." (Page 6)</div>
    </li>
    
            </ul>
            
            <h4>Suggestions for Improvement</h4>
            <ul>
            
    <li>
        <strong>Elaborate on potential mechanisms of creatine-CBT synergy</strong>
        
        <p>This is a high-impact improvement that would enhance the discussion&#x27;s contribution to the field. The discussion should elaborate on the potential mechanisms by which creatine might augment the effects of CBT. While the discussion mentions creatine&#x27;s interactions with monoamine systems in the context of antidepressant medications, it doesn&#x27;t fully explore how these mechanisms might relate to CBT. Expanding on this aspect would provide valuable insights into the synergistic effects of creatine and CBT and guide future research.</p>
        <div class="quote">"From this perspective, our finding that creatine could augment the effect of CBT is novel and its mechanistic basis unknown." (Page 5)</div>
        <p><strong>Implementation:</strong> Discuss potential mechanisms specific to the combination of creatine and CBT. For example, explore how creatine&#x27;s impact on brain energy metabolism might influence the neural processes involved in CBT, such as cognitive restructuring or emotional regulation. Consider discussing the potential role of creatine in enhancing neuroplasticity, which is thought to be a key mechanism underlying CBT&#x27;s effectiveness.</p>
    </li>
    
    <li>
        <strong>Discuss clinical implications and recommendations</strong>
        
        <p>This is a medium-impact improvement that would enhance the discussion&#x27;s clinical relevance. The discussion should address the potential implications of the findings for clinical practice. While the study suggests creatine&#x27;s potential as a safe and effective adjunct to CBT, the discussion does not explicitly discuss how these findings might translate into practical recommendations for clinicians.  Adding this discussion would bridge the gap between research and practice, increasing the study&#x27;s impact on patient care.</p>
        <div class="quote">"Because of the high dropout rates, however, any findings from this pilot study should be considered with caution, and no clinical recommendations can be made." (Page 6)</div>
        <p><strong>Implementation:</strong> Discuss the potential clinical implications of the findings. For example, suggest that clinicians consider creatine supplementation as a potential adjunctive treatment for patients who show a suboptimal response to CBT alone.  Address the practical aspects of implementing creatine supplementation in clinical practice, such as dosing, monitoring, and potential side effects.  Emphasize the need for shared decision-making between clinicians and patients regarding the use of creatine.</p>
    </li>
    
            </ul>
            
            
        </div>
        
    </div>
    
    <a href="#" class="back-to-top">↑ Back to Top</a>
    
    <script>
        window.onscroll = function() {
            var backToTopButton = document.querySelector('.back-to-top');
            if (document.body.scrollTop > 20 || document.documentElement.scrollTop > 20) {
                backToTopButton.style.display = 'block';
            } else {
                backToTopButton.style.display = 'none';
            }
        };
    </script>
</body>
</html>
    